MDGL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MDGL is a good buy right now for a beginner with a long-term horizon and $50,000-$100,000 to invest. My view is positive because the stock remains in an uptrend, analyst targets are still broadly above the current price, hedge funds are buying aggressively, and the company continues to post encouraging MASH-related commercial and pipeline milestones. Given the user’s impatience and preference to act now rather than wait for a better entry, this is a reasonable long-term buy rather than a stock to avoid.
MDGL is technically constructive. Price closed at 516.46, just above pivot support at 516.309 and below near-term resistance at 539.348. The moving averages are bullish with SMA_5 > SMA_20 > SMA_200, which supports an established uptrend. MACD histogram is positive at 3.842, though it is contracting, suggesting momentum is still positive but not accelerating. RSI_6 at 61.814 is neutral-to-bullish and does not show overbought stress. Overall, the chart favors continuation as long as the stock holds above the 516 pivot, with upside toward 539 and 553.6.
Recent news is positive: Madrigal and Suzhou Ribo Life Science nominated their first siRNA drug candidate, advancing a partnership aimed at MASH and enabling IND-enabling studies. This supports pipeline optionality beyond Rezdiffra. Analyst sentiment is also mixed-to-positive overall, with several firms maintaining Buy/Outperform-equivalent views and price targets well above the current price. Hedge funds are buying heavily, with buying up 176.46% over the last quarter. There is also no recent negative congress trading signal.
The main negatives are that BofA recently trimmed its target to $542 from $550 and kept only a Neutral rating, signaling some concern about whether Rezdiffra can sustain its launch pace. The MACD histogram is still positive but contracting, so momentum is not strengthening. The stock is trading below the recent market price of 528.1, and short-term pattern analysis implies a possible small near-term pullback before the longer trend resumes. Insiders are neutral, so there is no strong insider-buy confirmation.
No detailed financial snapshot was available in the data, so there is no latest-quarter revenue or earnings breakdown to assess. The available fundamental takeaway is indirect but favorable: analyst discussions cite continued Rezdiffra momentum, strongest patient adds since launch, and rising revenue expectations. That suggests the latest quarter season is likely being interpreted by the street as commercially positive, even though hard financial line items were not provided.
Analyst sentiment is constructive but not unanimous. Recent changes show modest target trims from BofA, Evercore ISI, and Canaccord, but the stance remains Neutral/Buy/Outperform rather than bearish. Truist raised its target sharply to 709 from 640 and kept Buy, while Clear Street lifted its target to 680 after Q1 and said momentum continues. The pros view is that Rezdiffra’s launch and patient growth are strong and could drive meaningful revenues. The cons view is that pace sustainability is now the key debate, and some analysts have started discounting peak revenue a bit.
